Form 4: Syros Pharmaceuticals CEO Conley Chee Reports Stock Transactions
SEC Form 4 Filing
CEO Conley Chee reports acquisition and disposal of Syros Pharmaceuticals (SYRS) common stock and restricted stock units.
Summary
- On March 31, 2024, Conley Chee, the President and CEO of Syros Pharmaceuticals, acquired 2,000 shares of common stock and 11,666 shares of common stock upon the vesting of restricted stock units.
- Also on March 31, 2024, Chee disposed of 2,000 restricted stock units and 11,666 restricted stock units.
- On April 1, 2024, Chee disposed of 3,500 shares of common stock at a price of $5.12 to cover tax withholding upon the release of restricted stock units.
- Following these transactions, Chee directly owns 22,504 shares of common stock and 4,000 and 23,334 restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock transactions by an executive.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for insiders of publicly traded companies, providing transparency into their trading activities.
Key Dates
| Date | Description |
|---|---|
| 02/15/2022 | Date of restricted stock unit award, vesting in four equal annual installments commencing on March 31, 2023. |
| 02/16/2023 | Date of restricted stock unit award, vesting in three equal annual installments commencing on March 31, 2024. |
| 03/31/2023 | First vesting date of restricted stock unit award granted on February 15, 2022. |
| 03/31/2024 | Date of common stock acquisition and disposal of restricted stock units. |
| 04/01/2024 | Date of common stock disposal for tax withholding. |
| 04/02/2024 | Date of Form 4 filing. |
Keywords
Syros Pharmaceuticals, SYRS, Conley Chee, stock, restricted stock units, Form 4, SEC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.